Molecular and clinicopathologic characterization of AML with isolated trisomy 4.

Acute myeloid leukemia (AML) with isolated trisomy 4 is rare. Associations with KIT mutations on chromosome 4q12 have been documented. The clinicopathologic features and mutational status of KIT, FLT3, NPM1, CEBPA, and RAS were assessed in 13 AML cases with isolated trisomy 4. There were 9 men and 4 women with a median age of 54 years. Median blast count was 84% (range, 24%-93%). Morphologic features varied across five 2008 World Health Organization categories. FLT3 (5/10) and NPM1 (4/10) mutations were observed at a frequency similar to normal-karyotype AML cases. KIT D816V (1/10), RAS (1/11; NRAS), and CEBPA (0/9) mutations were rare or absent. In 11 of 13 cases, complete remission was achieved. In 8 cases, relapse occurred, with median relapse-free survival of 11 months. Median overall survival was 28 months. AML with isolated trisomy 4 is rare and associated with high bone marrow blast counts and an intermediate to poor prognosis. KIT mutations are uncommon.

[1]  O. Griffith,et al.  Mitelman Database (Chromosome Aberrations and Gene Fusions in Cancer) , 2014 .

[2]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[3]  Rajyalakshmi Luthra,et al.  Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. , 2011, American journal of clinical pathology.

[4]  H. Koeppen,et al.  Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis , 2009, Cancer.

[5]  H. Koeppen,et al.  Application of COLD-PCR for improved detection of KRAS mutations in clinical samples , 2009, Modern Pathology.

[6]  L. Medeiros,et al.  Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. , 2009, American journal of clinical pathology.

[7]  R. Irons,et al.  Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations , 2006, European journal of haematology.

[8]  Yi Ning,et al.  Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. , 2006, Blood.

[9]  W. Hiddemann,et al.  1 KIT-D 816 mutations in AML 1-ETO positive AML are associated with impaired event-free and overall survival , 2005 .

[10]  A. Aventín,et al.  A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia. , 2006, Haematologica.

[11]  W. Hiddemann,et al.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.

[12]  L. Jeffrey Medeiros,et al.  Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type , 2005, British journal of haematology.

[13]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[14]  M. Taniwaki,et al.  Acute nonlymphocytic leukemia (M2) with chromosome abnormality trisomy 4 developing eight years after radiation therapy for breast cancer , 2004, Blut.

[15]  Alessandro Beghini,et al.  KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. , 2004, Haematologica.

[16]  M. Minden,et al.  Prognostic significance of trisomy 4 as the sole cytogenetic abnormality in acute myeloid leukemia. , 2003, Leukemia research.

[17]  D. Linch,et al.  Flt3 mutations and leukaemia , 2003, British journal of haematology.

[18]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[19]  Pu Zhang,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia , 2001, Nature Genetics.

[20]  G. Behre,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. , 2001, Nature genetics.

[21]  W. Hiddemann,et al.  Trisomy 4 in 'stem cell-like' leukemic cells of a patient with AML. , 1995, Leukemia.

[22]  D. Le Paslier,et al.  A YAC contig spanning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. , 1994, Genomics.

[23]  I. Sanada,et al.  Trisomy 4 in a case of acute myelogenous leukemia accompanied by subcutaneous soft tissue tumors. Report of a case and review of the literature. , 1993, Cancer genetics and cytogenetics.

[24]  S. Ferrari,et al.  Overexpression of c-kit in a leukemic cell population carrying a trisomy 4 and its relationship with the proliferative capacity. , 1993, Leukemia & lymphoma.

[25]  G. Leone,et al.  Trisomy 4 in acute myeloblastic and acute lymphoblastic leukemia. , 1993, Cancer genetics and cytogenetics.

[26]  United Kingdom Cancer Cytogenetic.  Primary, single, autosomal trisomies associated with haematological disorders. United Kingdom Cancer Cytogenetics Group (UKCCG). , 1992, Leukemia research.

[27]  A. Tabilio,et al.  Trisomy 4 in acute nonlymphocytic leukemia. Report of two cases and review of the literature. , 1992, Cancer genetics and cytogenetics.

[28]  B. Pedersen.  Trisomy 4: clinical picture, hematology, and survival. Presentation of two cases and review of the literature. , 1992, Hematologic pathology.

[29]  Y. Kao,et al.  Trisomy 4 in a case of acute undifferentiated myeloblastic leukemia with hand-mirror cells. , 1990, Cancer genetics and cytogenetics.

[30]  O. Haas,et al.  Trisomy 4: a specific karyotype anomaly in primary and secondary acute myeloid leukemia. , 1990, Leukemia.

[31]  H. Kantarjian,et al.  RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. , 1990, Blood.

[32]  O. Garson,et al.  Trisomy 4 in acute nonlymphocytic leukemia. An Australian case. , 1988, Cancer genetics and cytogenetics.

[33]  C. Hoyle,et al.  Two further cases of acute myeloid leukemia with trisomy 4. , 1988, Cancer genetics and cytogenetics.

[34]  D. Hossfeld,et al.  Trisomy 4 in two cases of acute myelomonocytic leukemia. , 1988, Cancer genetics and cytogenetics.

[35]  F. Hecht,et al.  Trisomy 4: an entity within acute nonlymphocytic leukemia. , 1987, Cancer genetics and cytogenetics.

[36]  G. Tricot,et al.  Trisomy 4 identifies a subset of acute nonlymphocytic leukemias. , 1986, Blood.

[37]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[38]  H. Muss,et al.  Chloroma and other myeloblastic tumors. , 1973, Blood.